Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25
Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash
Conference call and webcast to be held today, May 14th, at 8:30 AM EDT
NEW YORK, May 14, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the three months ended March 31, 2025.
Conference Call and Webcast
The webcast will take place on Wednesday, May 14, 2025, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
Business Highlights
"We are now better positioned than ever to capitalize on EsoGuard's significant clinical and commercial opportunity," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "We continue to make strong progress on multiple fronts – expanding our cash-pay and contracted programs targeting concierge medicine practices and self-insured employers, while also gaining traction with regional commercial insurers for EsoGuard coverage. With additional capital secured, we have extended our operational runway well beyond key upcoming reimbursement milestones, including Medicare. This positions us to accelerate commercialization efforts once these milestones are achieved."
Processed 3,034 EsoGuard® Esophageal DNA Tests in 1Q25,
Recognized $0.8 million in EsoGuard revenue for 1Q25.
Strengthened balance sheet with two common stock offerings with strategic long-term investors, netting approximately $30.6 million in proceeds; ended 1Q25 with over $40 million in proforma cash and extended runway well into 2026 and past key milestones.
Launched "Embrace the Future" campaign, showcasing the EsoCheck® Cell Collection Device's groundbreaking Collect+Protect™ Technology relative to antiquated sponge-on-a-string devices.
Partnered with a major health system to launch a comprehensive EsoGuard esophageal precancer testing program, expanding access to at-risk patients across the health system's digestive health, primary care, and concierge medicine programs.
Continued to gain traction in cash-pay concierge medicine and employer markets sales channels, both of which are expected to begin driving contractually-guaranteed revenue in 2H25.
NCI-sponsored study demonstrated EsoGuard effectively detects esophageal precancer in at-risk patients without GERD, supporting expanded indication and may increase market opportunity by as much as 70%.
Granted a U.S. patent for key technology underlying EsoGuard, adding to an already robust intellectual property portfolio. The patent covers proprietary methods using methylation of the SqBE18 (CCNA1) gene to detect esophageal precancer and cancer
Financial Results
For the three months ended March 31, 2025, EsoGuard related revenues were $0.8 million. Operating expenses were approximately $13.3 million, which included stock-based compensation expenses of $1.0 million. GAAP net loss attributable to common stockholders was approximately $36.0 million or $(0.52) per common share.
As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company's financial results, the Company's non-GAAP adjusted loss for the three months ended March 31, 2025, was approximately $11.2 million or $(0.16) per common share.
Lucid had cash and cash equivalents of $25.2 million as of March 31, 2025, compared to $22.4 million as of December 31, 2024. Subsequent to March 31, 2025, the Company completed an underwritten public offering of its common stock for net proceeds of $16.1 million.
The unaudited financial results for the three months ended March 31, 2025, were filed with the SEC on Form 10-Q on May 13, 2025, and available at www.luciddx.com or www.sec.gov.
Lucid Non-GAAP Measures
To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense and other non-cash income and expenses, if any. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.
Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.
Non-GAAP financial measures are provided to enhance readers' overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment, and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.
A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three months ended March 31, 2025, and 2024 are as follows:
Condensed consolidated statements of operations (unaudited)
(in thousands except per-share amounts)For the three months ended
March 31,
20252024Revenue$ 828$ 1,001Operating expenses13,31511,793
Other (Income) expense14,421(180)
Net Loss(26,908)(10,612)
Net income (loss) per common share, basic and diluted$ (0.52)$ (0.40)
Net loss attributable to common stockholders(36,018)(18,108)
Preferred Stock dividends and deemed dividends9,1107,496
Net income (loss) as reported(26,908)(10,612)
Adjustments:
Depreciation and amortization expense1221501
Interest expense, net2(57)(56)
EBITDA(26,744)(10,167)Other non-cash or financing related expenses:
Stock-based compensation expense31,030933
Operating expenses issued in stock17423
Change in FV convertible debt214,478(291)
Debt extinguishments loss - Senior Secured Convertible Note2—167
Non-GAAP adjusted (loss)$ (11,162)$ (9,335)
Basic and Diluted shares outstanding68,79645,014
Non-GAAP adjusted (loss) income per share$(0.16)$(0.21)1 Included in general and administrative expenses in the financial statements.2 Included in other income and expenses.3 Stock-based compensation ("SBC") expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses:
Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses
(in thousands except per-share amounts)For the three months ended
March 31,
20252024
Cost of revenues$ 1,551$ 1,656
Stock-based compensation expense3(71)(36)
Net cost of revenues1,4801,620Amortization of intangible assets105372Sales and marketing4,0694,194
Stock-based compensation expense3(239)(350)
Net sales and marketing3,8303,844General and administrative6,1624,070
Depreciation expense(116)(129)
Operating expenses issued in stock(74)(23)
Stock-based compensation expense3(601)(330)
Net general and administrative5,3713,588Research and development1,4281,501
Stock-based compensation expense3(119)(217)
Net research and development1,3091,284Total operating expenses13,31511,793
Depreciation and amortization expense(221)(501)
Operating expenses issued in stock(74)(23)
Stock-based compensation expense3(1,030)(933)
Net operating expenses$ 11,990$ 10,336About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.
Forward-Looking StatementsThis press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2025-financial-results-302455197.html
SOURCE Lucid Diagnostics
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time Business News
18 minutes ago
- Time Business News
Corrado Garibaldi: The Contrarian Trader Who Profits When Others Panic
In the high-stakes world of Trading Invest Celebrity Italy, where herd mentality often leads to costly mistakes, one investor has built his success on a simple but ruthless principle: When others zig, zag. Corrado Garibaldi—better known in finance circles as Lord Conrad—has carved a reputation as a maverick trader who thrives on going against the grain. His mantra? 'Buy the fear. Sell the euphoria.' The Unconventional Path to Trading Mastery Unlike Wall Street's typical Ivy League-educated financiers, Garibaldi is a self-made trader with no formal finance background. An Italian native, he entered the markets out of necessity, driven by a desire to take control of his financial future. 'I never studied economics or attended business school,' he admits. 'I learned by doing—making mistakes, refining strategies, and realizing that most people lose money because they follow the crowd.' The Contrarian Edge: Why 99.9999% of Traders Are Wrong Garibaldi's core philosophy is rooted in contrarian investing—a strategy that capitalizes on market overreactions. 'When everyone is buying, I'm selling. When panic sets in, I'm buying,' he says. 'The masses are almost always wrong at extremes. That's where the real opportunities lie.' This approach has allowed him to profit from major market swings, whether during the crypto crashes of 2022 or the AI stock frenzy of 2024. Two Sides of the Same Coin: Trader by Day, Investor by Night Garibaldi operates in two distinct modes: As a trader, he's a speed-focused tactician, scalping the Nasdaq and executing swing trades with military precision. As an investor, he's a patient wealth-builder, holding long-term positions in giants like Apple, Microsoft, and Tesla while diversifying into bonds and crypto. His portfolio strategy? 99% long-term holdings, 1% high-octane trading—a balance that maximizes growth while keeping risk in check. The Trader's Mindset: Why Psychology Beats IQ For Garibaldi, trading isn't just about charts—it's about mastering fear and greed. 'Most traders fail because they let emotions drive decisions,' he says. 'The key is to stay mechanical. Follow the plan, not the panic.' He enforces strict rules: ✔ Never risk more than 1% on a single trade ✔ Always use stop-losses ✔ Ignore hype—trade the data, not the narrative 2025 and Beyond: Adapt or Die In an era of AI-driven markets and geopolitical volatility, Garibaldi remains agile—constantly refining strategies and engaging with traders worldwide via social media. 'Markets change. If you're not learning, you're losing,' he warns. Final Word: The Slow Road to Trading Success For aspiring traders, Garibaldi's advice is refreshingly honest: 'This isn't a get-rich-quick game. Consistency beats luck. Small, smart gains compound over time—that's how real wealth is built.' Want to see his strategies in action? Visit Trading Invest Celebrity Italy. TIME BUSINESS NEWS

Yahoo
23 minutes ago
- Yahoo
Mercialys: Acquisition of Saint-Genis 2, a Leading Shopping Center of Greater Lyon
PARIS, June 10, 2025--(BUSINESS WIRE)--Regulatory News: Mercialys (Paris:MERY): An asset perfectly aligned with Mercialys' ambitions Mercialys announces the acquisition of the Saint-Genis 2 shopping center, located in western Lyon, within a catchment area of 700,000 inhabitants—home to the highest-income households in the city. Greater Lyon stands as the second largest consumer market in France after Paris, ahead of Marseille and Toulouse, where Mercialys already holds major assets. This acquisition fully aligns with the Group's strategy to strengthen its presence in the country's most dynamic regions. Acquired for a total price of €146 million including transfer taxes, the asset offers an immediate yield significantly above the Company's investment criteria and presents substantial medium-term value creation potential. A high-performance, leading-retail destination The center had undergone, a few years ago, a comprehensive renovation and environmental performance upgrade program amounting to €45 million. With almost 100 well diversified retail brands and the second most successful hypermarket in the Auchan group (outside the scope of this transaction), it is the largest shopping center in the western part of the Lyon metropolitan area. Beyond its many strengths, the robustness of its catchment area endows this asset with further optimization potential. Its commercial performance can be enhanced through the re-tenanting and consolidation of its retail mix, aligning it with the Company's standards which boast an average occupancy rate of 98% across its 33 strategic assets. An investment initiating a new momentum for the Company This investment represents a unique opportunity for Mercialys to reinforce its position as a key player in the French retail property sector. Guided by a strategy focused on sustainability and operational excellence, the Company intends to fully leverage the strengths of this asset while pursuing its growth objectives. As part of this transaction, Mercialys was advised by Screeb Notarial Office, Arsène for tax matters, and Haldis for technical due diligence. The seller was represented by Michelez Notarial Office, with BNP Paribas and Morgan Stanley acting as financial advisors. This press release is available on presentation of these results is also available online, in the following section:Investors / News and press releases / Financial press releases About Mercialys Mercialys is one of France's leading real estate companies. It is specialized in the holding, management and transformation of retail spaces, anticipating consumer trends, on its own behalf and for third parties. At December 31, 2024, Mercialys had a real estate portfolio valued at Euro 2.8 billion (including transfer taxes). Its portfolio of 1,927 leases represents an annualized rental base of Euro 169.2 million. Mercialys has been listed on the stock market since October 12, 2005 (ticker: MERY) and has "SIIC" real estate investment trust (REIT) tax status. Part of the SBF 120 and Euronext Paris Compartment A, it had 93,886,501 shares outstanding at December 31, 2024. IMPORTANT INFORMATION This press release contains certain forward-looking statements regarding future events, trends, projects or targets. These forward-looking statements are subject to identified and unidentified risks and uncertainties that could cause actual results to differ materially from the results anticipated in the forward-looking statements. Please refer to Mercialys' Universal Registration Document available at for the year ended December 31, 2024 for more details regarding certain factors, risks and uncertainties that could affect Mercialys' business. Mercialys makes no undertaking in any form to publish updates or adjustments to these forward-looking statements, nor to report new information, new future events or any other circumstances that might cause these statements to be revised. View source version on Contacts Analyst and investor Olivier PouteauTel: +33 (0)6 30 13 27 31Email: opouteau@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
27 minutes ago
- Business Wire
Mercialys: Acquisition of Saint-Genis 2, a Leading Shopping Center of Greater Lyon
Mercialys (Paris:MERY): An asset perfectly aligned with Mercialys' ambitions Mercialys announces the acquisition of the Saint-Genis 2 shopping center, located in western Lyon, within a catchment area of 700,000 inhabitants—home to the highest-income households in the city. Greater Lyon stands as the second largest consumer market in France after Paris, ahead of Marseille and Toulouse, where Mercialys already holds major assets. This acquisition fully aligns with the Group's strategy to strengthen its presence in the country's most dynamic regions. Acquired for a total price of €146 million including transfer taxes, the asset offers an immediate yield significantly above the Company's investment criteria and presents substantial medium-term value creation potential. A high-performance, leading-retail destination The center had undergone, a few years ago, a comprehensive renovation and environmental performance upgrade program amounting to €45 million. With almost 100 well diversified retail brands and the second most successful hypermarket in the Auchan group (outside the scope of this transaction), it is the largest shopping center in the western part of the Lyon metropolitan area. Beyond its many strengths, the robustness of its catchment area endows this asset with further optimization potential. Its commercial performance can be enhanced through the re-tenanting and consolidation of its retail mix, aligning it with the Company's standards which boast an average occupancy rate of 98% across its 33 strategic assets. An investment initiating a new momentum for the Company This investment represents a unique opportunity for Mercialys to reinforce its position as a key player in the French retail property sector. Guided by a strategy focused on sustainability and operational excellence, the Company intends to fully leverage the strengths of this asset while pursuing its growth objectives. As part of this transaction, Mercialys was advised by Screeb Notarial Office, Arsène for tax matters, and Haldis for technical due diligence. The seller was represented by Michelez Notarial Office, with BNP Paribas and Morgan Stanley acting as financial advisors. This press release is available on A presentation of these results is also available online, in the following section: Investors / News and press releases / Financial press releases About Mercialys Mercialys is one of France's leading real estate companies. It is specialized in the holding, management and transformation of retail spaces, anticipating consumer trends, on its own behalf and for third parties. At December 31, 2024, Mercialys had a real estate portfolio valued at Euro 2.8 billion (including transfer taxes). Its portfolio of 1,927 leases represents an annualized rental base of Euro 169.2 million. Mercialys has been listed on the stock market since October 12, 2005 (ticker: MERY) and has 'SIIC' real estate investment trust (REIT) tax status. Part of the SBF 120 and Euronext Paris Compartment A, it had 93,886,501 shares outstanding at December 31, 2024. IMPORTANT INFORMATION This press release contains certain forward-looking statements regarding future events, trends, projects or targets. These forward-looking statements are subject to identified and unidentified risks and uncertainties that could cause actual results to differ materially from the results anticipated in the forward-looking statements. Please refer to Mercialys' Universal Registration Document available at for the year ended December 31, 2024 for more details regarding certain factors, risks and uncertainties that could affect Mercialys' business. Mercialys makes no undertaking in any form to publish updates or adjustments to these forward-looking statements, nor to report new information, new future events or any other circumstances that might cause these statements to be revised.